Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer — PILOT  

CLDN18.2-positive Adenocarcinoma of Esophagus Clinical Trial

Official title: Multicenter, Open-label, Exploratory Phase I Pilot Study to Investigate Safety, Pharmacodynamics, and Pharmacokinetics of Immunological Effects and Activity of Combining Multiple Doses of IMAB362 With Immunomodulation (Zoledronic Acid, Interleukin-2) in Patients With Advanced Adenocarcinoma of the Stomach, the Lower Esophagus, or the Gastroesophageal Junction

Status Completed

Clinical Trial Summary

The purpose of the trial is to assess the immunological effects and their kinetics, the safety and activity of IMAB362 plus Zoledronic acid with/without low to intermediate doses of Interleukin-2 in subjects with advanced gastroesophageal cancer.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Adenocarcinoma
• CLDN18.2-positive Adenocarcinoma of Esophagus
• CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction
• CLDN18.2-positive Gastric Adenocarcinoma

• NCT number: NCT01671774
• Study type: Interventional
• Source: Astellas Pharma Inc
• Status: Completed
• Phase: Phase 1
• Start date: October 16, 2012
• Completion date: October 13, 2014